This article was originally published here J Int Med Res. Continue reading →

This article was originally published here J Cardiovasc Pharmacol. 2020 Dec;76(6):678-683. Continue reading →

Coronary artery calcium (CAC) score as a measure of plaque burden more reliably predicts future cardiovascular (CV) risk in patients with suspected coronary disease (CAD) than whether or not the disease is obstructive, a large retrospective study suggests. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. Continue reading →

Patients with chronic lymphocytic leukemia (CLL) who received treatment with single-agent acalabrutinib (Calquence) experienced a low incidence of cardiac toxicities leading to treatment discontinuation, according to data from a pooled analysis across 4 clinical trials presented during the 2020 ASH Annual Meeting & Exposition.1 Results showed that 17% (n = 129) of 762 patients with CLL who received treatment with the second-generation BTK inhibitor as a monotherapy experienced cardiac toxicity of any grade at a median follow-up of 25.9 months, which led to treatment discontinuation in 7 patients (0.9%). Continue reading →

Abstract Objective To determine the association between levels of low density lipoprotein cholesterol (LDL-C) and all cause mortality, and the concentration of LDL-C associated with the lowest risk of all cause mortality in the general population. Design Prospective cohort study Continue reading →

This nationwide retrospective cohort study used the National Health Insurance Research Database of Taiwan to compare the impact of bleeding on clinical outcomes in patients with acute myocardial infarction (AMI) versus chronic coronary syndrome (CCS). Continue reading →

Living near hydraulic fracturing is associated with increased risk of hospitalization in people with heart failure (HF), a new study from Pennsylvania suggests. The link was strongest among those with more severe heart failure but patients with either HF phenotype showed this association of increased risk with exposure to fracking activities, according to the investigators, led by Tara P. McAlexander, PhD, MPH, Drexel University Dornsife School of Public Health in Philadelphia Continue reading →

The FDA has granted a Breakthrough Therapy designation to the KRAS G12C inhibitor sotorasib for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who harbored a KRAS G12C mutation as detected by an FDA-approved test and following at least 1 prior line of systemic therapy, announced Amgen, developer of the drug, in a press release. "Breakthrough Therapy designation and Real-Time Oncology Review bring Amgen closer to potentially providing a targeted therapy to patients with aKRAS G12Cmutation and establishing sotorasib as the foundational therapy inKRAS G12C-driven cancers," saidDavid M Continue reading →